<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <JournalTitle>Cancer Case Reports</JournalTitle>
      <Volume-Issue>Volume 2; Issue 2</Volume-Issue>
      <ArticleType>Cancer Research</ArticleType>
      <ArticleTitle>A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report</ArticleTitle>
      <Abstract>A novel treatment for prostate cancer, based on the Tvec /pembroluzimab technology – supported by activation of innate immunity is reported. The effect has been striking. Reduction of PSA from 60 µg/Liter to undetectable in 6 weeks, reduction of serum LDH from almost 1000 U/L to under 200 (normal) in 8 weeks, extensive necrosis in the tumor tissue as revealed by MR. The treatment gave no serious side-effects.</Abstract>
      <Keywords>Prostate,Cancer,Tvec,Pembroluzimab,Innate Immunity</Keywords>
        <Abstract>https://cancercasereports.com/ubijournal-v1copy/journals/abstract.php?article_id=13452&amp;title=A Novel Effective Treatment of Advanced Prostate Cancer: A Single Case Report</Abstract>
        <References>Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 9th edition, Elsevier, 2017&#13;
Bogwald J, Hoffman J, Seljelid R. Coupling of polysaccharides by means of chloroacetaldehyde dimethyl acetal to amines or protein by reductive amination. Carbohydrate Res 1986; 148: 101-107.&#13;
Gordon S. The macrophage: Past, present and future. Eur J Immunol 2007; 37: S9-S17.&#13;
Kohlhapp FJ and Kaufman HL. Molecular Pathways: Mechanism of Action for Talimogens Laherparepvcc, a New Oncolytic Virus Immunotherapy. Clinical Cancer Res 2016; 22: 1048.&#13;
Li Y, Cozzi PJ, Russell P. Promising tumor-associated antigens for future prostate cancer therapy. Medicinal Research Reviews 2010; 30: 67-101.&#13;
Paul WE. Fundamental Immunology. Wolters Kluwer Health/Lippincott Williams and; Wilkins, Philadelphia, 2013.&#13;
Seljelid R, Bogwald J, Lundwall A. Glycan stimulation of macrophages in vitro. Exp Cell Res 1981; 13: 121-129.&#13;
Seljelid R, Rasmussen LT, Larm O, Hoffman J. The protective effect of beta 1-3 D-glucan derivatized plastic beads against Escherichia coli infection in mice. Scand J Immunol 1987; 25: 55-60.&#13;
Seljelid R. A watersoluble aminated and;szlig;1-3 glucan Derivative causes Regression of Solid Tumors in mice. Bioscience Reports 1986; 9: 845-851.&#13;
Seljelid R. Tumour Regression after Treatment with aminated and;szlig;1-3 polyglucose is initiated by circulatory failure. Scand J Immunol 1989; 29: 181-192.&#13;
Sweeney K and Halldand;eacute;n G. Oncolytic adenovirus – mediated therapy for Prostate cancer. Oncolytic Virotherapy 2012; 5: 45-57.&#13;
Trehub Y and Gavrilov A. Oncolytic virus in Immunotherapeutic Agents. In Springer Nature Cancer Immunology Rezaei N. (Ed.) 2021; 2021: 509-541.</References>